FDA Cleared Sepsis Test Becomes First in New Class of ED-Focused Diagnostic Tools
By LabMedica International staff writers Posted on 23 Jan 2023 |

Sepsis is a leading cause of death across the world and causes over 270,000 deaths annually in the U.S. It is caused by the body’s overwhelming life-threatening response to an infection, which triggers a chain reaction and rapidly leads to tissue damage, organ failure, and death. If sepsis remains untreated, the risk of death from the condition increases by 8% every hour. Almost 80% of sepsis deaths can be prevented with rapid diagnosis and treatment - making early detection vital to improving clinical, operational, and financial outcomes. Now, a new test has received U.S. Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the 30 million adult patients who present to US emergency departments (ED) annually with signs and symptoms of the infection.
Cytovale’s (San Francisco, CA, USA) IntelliSep sepsis test is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis and contribute to rapid life-saving decisions. The groundbreaking diagnostic tool provides test results in less than 10 minutes, helping clinicians to recognize sepsis and supporting critical time-sensitive clinical decisions. The first in a new class of ED-focused diagnostic tools that assess host response, the IntelliSep sepsis test is a simple, fast, and intuitive solution that provides actionable answers directly from a standard blood draw.
IntelliSep’s innovative technology, which is run on the Cytovale System, assesses the body’s immune response to an infection using immune cell morphology. The biophysical properties of white blood cells from septic patients demonstrate distinct changes when subjected to pressure that are captured in images and then characterized using a proprietary algorithm to produce a result. By applying pressure to tens of thousands of cells and observing their reaction, IntelliSep provides valuable new insights related to sepsis.
IntelliSep categorizes patients into three bands depending on their probability of sepsis, with Band 1 indicating a low probability of sepsis and Band 3 indicating a high probability of sepsis. The results can equip providers with a tool to optimize clinical outcomes and empower hospitals to improve resource utilization and achieve operational excellence. IntelliSep can also support hospital efforts to meet guidelines set by the Centers for Medicare & Medicaid Services (CMS) for timely sepsis treatment, known as SEP-1.
“This clearance is a pivotal step forward in Cytovale’s commitment to early detection technologies to improve health," said Cytovale co-founder and CEO Ajay Shah. "Every minute is crucial in identifying sepsis, and IntelliSep has the potential to transform clinical approaches to sepsis triage and diagnosis and save countless lives."
Related Links:
Cytovale
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more